CD4 and tuberculosis: Since no single T cell subset has been definitively correlated with protection, inducing a diverse CD4+ T cell response remains a key objective in TB vaccine development, supported by strong and consistent evidence of CD4+ T cell-mediated protection in both preclinical and clinical studies (11–13).